Margarida Maia, PhD, science writer —

Harbour BioMed has submitted a new, revised version of a biologics license application (BLA) to China’s regulatory agency requesting the approval of batoclimab (HBM9161) to treat generalized myasthenia gravis (MG). The original application was accepted for review last year by China’s National Medical Products Administration (NMPA). The…

Patients who received Vyvgart (efgartigimod alfa) as part of an expanded access program required more frequent dosing to treat generalized myasthenia gravis (gMG) than what was used during clinical testing, according to a small study in the Netherlands. Study findings also showed that more than half of the…

Butyric acid from gut bacteria, or supplementation with its salt form butyrate, could become potential treatments for myasthenia gravis (MG) by working to restore the function of immune cells that limit the production of disease-causing antibodies. That’s according to the findings of a new study in human cells and…

Many of the adults with generalized myasthenia gravis (gMG) who took part in ADAPT, a Phase 3 clinical study of Vyvgart (efgartigimod), and its open-label extension, ADAPT+, experienced minimal or no symptoms and a quality of life closer to that of healthy adults. While Vyvgart is approved to…

Ultomiris (ravulizumab) continues to be well tolerated and to keep symptoms of generalized myasthenia gravis (gMG) under control when used for more than three years, according to a final analysis of data from an open-label extension of the Phase 3 CHAMPION-MG trial. The data were presented by Tuan…

NMD Pharma has been cleared by the U.S. Food and Drug Administration (FDA) to start a Phase 2b clinical trial testing NMD670, an investigational CIC-1 inhibitor being developed for generalized myasthenia gravis (gMG). Planned to launch in the coming months in the U.S. and Europe, the trial will…

Enspryng (satralizumab), which Chugai Pharmaceutical is testing for generalized myasthenia gravis (gMG), showed a significant benefit in easing disease symptoms and their impact on daily life when used along with standard of care. Positive results from the placebo-controlled Phase 3 LUMINESCE trial (NCT04963270), however, did not…

Higher levels of an immune protein called macrophage migration inhibitory factor (MIF) in the blood are linked to more severe myasthenia gravis (MG) and an increased risk of relapse, according to a study. The findings suggest MIF could be used as a biomarker of MG disease activity, the study’s…

Periocular (around-the-eyeball) injections of triamcinolone, a corticosteroid, may ease early symptoms of ocular myasthenia gravis (MG) and reduce the need for patients to take oral medications that have more potential side effects, a study has found. The study, “A controlled clinical study on efficacy and safety of periocular…

TOL2, a medication being developed by Toleranzia for the treatment of myasthenia gravis (MG), was found to be well tolerated in a preclinical toxicology study, supporting the company’s decision to test it in humans. No side effects were observed when lab animals were given a dose of TOL2…